Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001144204-10-002774)

Filing Details

Accession Number:: 0001144204-10-002774
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-01-20 12:00:00
Reporting Period:: 2010-01-19

Filing Date:: 2010-01-20
Accepted Time:: 2010-01-20 17:09:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1318641	Cleveland Biolabs Inc	CBLI	Services-Commercial Physical & Biological Research (8731)	200077155

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1370083	V Andrei Gudkov	73 High Street Buffalo NY 14203	Chief Scientific Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-01-19	400	$3.87	1,529,200	No	4	S	Direct
Common Stock	Disposition	2010-01-19	500	$3.90	1,528,700	No	4	S	Direct
Common Stock	Disposition	2010-01-19	300	$3.91	1,528,400	No	4	S	Direct
Common Stock	Disposition	2010-01-19	189	$3.86	1,528,211	No	4	S	Direct
Common Stock	Disposition	2010-01-19	1,500	$3.88	1,526,711	No	4	S	Direct
Common Stock	Disposition	2010-01-19	1,411	$3.89	1,525,300	No	4	S	Direct
Common Stock	Disposition	2010-01-19	700	$3.85	1,524,600	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Employee Stock Options (Right to Buy)	$8.36	2007-04-06	2017-04-05	37,500	37,500	Direct
Common Stock	Employee Stock Options (Right to Buy)	$4.00	2008-02-04	2018-02-03	137,250	174,750	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2017-04-05	37,500	37,500	Direct
2018-02-03	137,250	174,750	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.